Novartis Ag (NVS) Change in Intangibles (2009 - 2026)
Novartis Ag (NVS) posted Change in Intangibles of -$461.0 million for Q1 2026, down 511.61% sequentially from $112.0 million in Q4 2025.
Novartis Ag (NVS) Change in Intangibles (2009 - 2026) Analysis & Trends
Novartis Ag has reported Change in Intangibles for 14 years, with the latest figure at -$461.0 million in Q1 2026.
- Quarterly Change in Intangibles changed N/A year-over-year to -$461.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$524.0 million (changed N/A YoY) and the FY2025 annual result came in at $164.0 million, up 105.0% from the prior year.
- Change in Intangibles eased to -$461.0 million in Q1 2026 per NVS's latest filing, from $112.0 million in the prior quarter.
- Over five years, Change in Intangibles peaked at $130.0 million in Q1 2023 and troughed at -$929.0 million in Q1 2024.
- A 5-year average of -$145.8 million and a median of $11.5 million in 2022 frame the typical range for Change in Intangibles.
- The sharpest annual moves came in 2023 and 2024: Change in Intangibles plunged 14166.67% in 2023, then jumped 1750.0% in 2024.
- Over 5 years, Change in Intangibles stood at -$192.0 million in 2022, then jumped by 101.04% to $2.0 million in 2023, then surged by 1750.0% to $37.0 million in 2024, then soared by 202.7% to $112.0 million in 2025, then plunged by 511.61% to -$461.0 million in 2026.
- According to Business Quant data, Change in Intangibles over the past three periods registered -$461.0 million, $112.0 million, and $52.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 393.11 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -461.00 Mn |
| Mar 31, 2026 | -461.00 Mn |
| Dec 31, 2025 | 112.00 Mn |
| Dec 31, 2025 | 112.00 Mn |
| Sep 30, 2025 | 52.00 Mn |
| Sep 30, 2025 | 52.00 Mn |
| Jun 30, 2025 | -227.00 Mn |
| Jun 30, 2025 | -227.00 Mn |
| Dec 31, 2024 | 37.00 Mn |
| Dec 31, 2024 | 37.00 Mn |
| Sep 30, 2024 | 23.00 Mn |
| Sep 30, 2024 | 23.00 Mn |
| Jun 30, 2024 | 20.00 Mn |
| Jun 30, 2024 | 20.00 Mn |
| Mar 31, 2024 | -929.00 Mn |
| Mar 31, 2024 | -929.00 Mn |
| Dec 31, 2023 | 2.00 Mn |
| Dec 31, 2023 | 2.00 Mn |
| Sep 30, 2023 | -422.00 Mn |
| Sep 30, 2023 | -422.00 Mn |